Reports Q4 revenue $380.1M, consensus $387.61M. "We had an outstanding fourth quarter and 2022, with revenues from our two cornerstone medicines, BRUKINSA(R) and tislelizumab, dramatically increasing as our global team continues to bring these innovative therapies to more patients and their caregivers," said John V. Oyler, Co-Founder, Chairman and Chief Executive Officer at BeiGene. "The final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile compared to IMBRUVICA(R) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and the recent U.S. FDA approval for BRUKINSA in adult patients with CLL/SLL were the most impactful of many recent milestones for our company and a testament to our commitment to following the science."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BGNE:
- BeiGene announces China NMPA approval for tislelizumab
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- BeiGene price target raised to $350 from $290 at Guggenheim
- BeiGene announces FDA approval of Brukinsa for CLL
- BeiGene announces MHRA granted marketing authorization for BRUKINSA
